07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

BioPharma Forest, KineMed deal

Biopharma Forest granted KineMed exclusive, worldwide rights, except Japan, Korea, Taiwan and China, to develop and commercialize synthetic ghrelin for all indications except amyotrophic lateral sclerosis. KineMed will develop the product and apply its technology...